Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ATXS

Astria Therapeutics Inc

Dec 13 • 04:00PM ET

9.52

Dollar change -0.29
Percentage change -2.96	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX PFE GILD AMGN BIIB SRPT ALNY NBIX BLUE

| Held by: VTI IWM VXF XBI IWO DWAS VTWO SCHA VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.09	Insider Own	14.49%	Shs Outstand	56.43M	Perf Week	-8.02%
Market Cap	521.37M	Forward P/E	-	EPS next Y	-1.80	Insider Trans	0.00%	Shs Float	48.26M	Perf Month	-10.27%
Income	-100.04M	PEG	-	EPS next Q	-0.45	Inst Own	87.20%	Short Float	6.52%	Perf Quarter	-15.23%
Sales	0.00M	P/S	-	EPS this Y	29.93%	Inst Trans	2.62%	Short Ratio	9.36	Perf Half Y	4.04%
Book/sh	4.36	P/B	2.18	EPS next Y	-6.25%	ROA	-36.02%	Short Interest	3.15M	Perf Year	62.46%
Cash/sh	6.29	P/C	1.51	EPS next 5Y	-	ROE	-38.03%	52W Range	5.22 - 16.90	Perf YTD	23.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	39.84%	ROI	-28.92%	52W High	-43.67%	Beta	0.67
Dividend TTM	-	Quick Ratio	22.38	Sales past 5Y	0.00%	Gross Margin	-	52W Low	82.38%	ATR (14)	0.66
Dividend Ex-Date	Mar 29, 2005	Current Ratio	22.38	EPS Y/Y TTM	4.90%	Oper. Margin	-	RSI (14)	40.36	Volatility	7.34% 7.10%
Employees	59	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	26.43
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	32.89%	Payout	-	Rel Volume	0.58	Prev Close	9.81
Sales Surprise	-	EPS Surprise	0.40%	Sales Q/Q	-	Earnings	Nov 13 AMC	Avg Volume	336.08K	Price	9.52
SMA20	-4.28%	SMA50	-12.25%	SMA200	-13.43%	Trades		Volume	195,615	Change	-2.96%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-29-24	Initiated	TD Cowen	Buy	$35
Mar-28-23	Initiated	Evercore ISI	Outperform	$18

Dec-11-24 08:00AM	Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE (Business Wire)
Dec-10-24 08:00AM	Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis (Business Wire)
Dec-03-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-24 04:10PM	Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire)
08:00AM	Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference (Business Wire)
04:10PM	Loading…
Nov-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting (Business Wire)
Oct-21-24 08:00AM	Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (Business Wire)
Oct-17-24 08:16AM	Astria Therapeutics' navenibart gains orphan medicinal status from EC (Pharmaceutical Business Review)
Oct-16-24 08:00AM	European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics Investigational Therapy for the Treatment of Hereditary Angioedema (Business Wire)
Oct-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-30-24 08:00AM	Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema (Business Wire)
Sep-27-24 08:00AM	Astria Therapeutics to Present at Upcoming Global Angioedema Forum (Business Wire)
Sep-19-24 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress (Business Wire) +6.37%
Sep-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:00AM	Loading…
Aug-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Bradykinin Symposium (Business Wire)
Aug-29-24 08:00AM	Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-12-24 04:10PM	Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire) +7.48%
04:00PM	Astria Therapeutics Chooses Ypsomed's YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema (Business Wire)
Aug-07-24 08:00AM	Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference (Business Wire)
Aug-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.61% -5.36%
Jul-02-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-04-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-24 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference (Business Wire)
May-24-24 08:00AM	Astria Therapeutics to Present at Upcoming Eastern Allergy Conference (Business Wire)
May-23-24 08:00AM	Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress (Business Wire)
May-09-24 04:10PM	Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (Business Wire) +6.27%
May-08-24 08:00AM	Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting (Business Wire)
May-02-24 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-09-24 08:00AM	Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors (Business Wire)
07:00PM	Loading…
Apr-03-24 07:00PM	Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS) (GuruFocus.com) -5.47%
04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-25-24 07:30AM	Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE (Business Wire)
Mar-05-24 04:10PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.14%
Mar-04-24 10:52PM	ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
04:10PM	Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update (Business Wire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-20-24 08:00AM	Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting (Business Wire)
Feb-06-24 08:00AM	Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference (Business Wire) +6.25%
Feb-05-24 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.95%
Jan-30-24 07:29PM	Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (GuruFocus.com) +6.62%
09:08AM	Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering (Business Wire)
Dec-04-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-27-23 08:00AM	Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress (Business Wire)
Nov-21-23 08:00AM	Astria Therapeutics to Present at Upcoming 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-14-23 01:07PM	Astria Therapeutics, Inc. (NASDAQ:ATXS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 11:07AM	Astria Therapeutics Inc (ATXS) Reports Q3 Financial Results and Corporate Developments (GuruFocus.com)
08:00AM	Astria Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update (Business Wire)
Nov-10-23 08:00AM	Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting (Business Wire)
Nov-09-23 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference (Business Wire)
Nov-03-23 08:10AM	Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting (Business Wire)
Nov-02-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-30-23 08:00AM	Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th (Business Wire)
Oct-11-23 07:14PM	Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering (Business Wire)
05:10PM	Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio (Business Wire)
Oct-03-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-23 08:00AM	Astria Therapeutics to Participate in Upcoming Investor Conferences (Business Wire)
Aug-31-23 08:00AM	Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics (Business Wire)
Aug-30-23 10:01AM	2 Strong Buy Stocks Under $10 That Oppenheimer Sees Surging Over 200% Heres Why They Could Jump (TipRanks)
Aug-25-23 08:00AM	Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference (Business Wire)
Aug-07-23 04:10PM	Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update (Business Wire)
Aug-02-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-20-23 08:00AM	Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema (Business Wire)
Jul-17-23 08:00AM	Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations (Business Wire)
Jul-14-23 08:00AM	Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit (Business Wire)
Jul-06-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-06-23 08:00AM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-23 08:00AM	Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting (Business Wire) +5.55%
May-31-23 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference (Business Wire)
May-11-23 04:10PM	Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update (Business Wire)
May-02-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.17%
Apr-28-23 08:00AM	Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop (Business Wire) +8.03%
Apr-19-23 08:00AM	Astria Therapeutics Names Andrea Matthews Chief Business Officer (Business Wire) +5.37%
Apr-04-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.88%
Mar-22-23 08:00AM	Astria Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update (Business Wire)
Mar-08-23 08:00AM	Astria Therapeutics to Report Fourth Quarter/Full Year 2022 Financial Results and Recent Corporate Developments on Wednesday, March 22nd (Business Wire)
Mar-06-23 08:00AM	Astria Therapeutics to Present at Upcoming Oppenheimer 33rd Annual Healthcare Conference (Business Wire)
Mar-02-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.19%
Feb-24-23 08:00AM	Astria Therapeutics Presents Additional Data Supporting STAR-0215 Profile as a Long-Acting Preventative Therapy for Hereditary Angioedema at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting (Business Wire)
Feb-21-23 08:00AM	Astria Therapeutics to Present New STAR-0215 Data at the 2023 American Academy of Allergy, Asthma, and Immunology Annual Meeting (Business Wire) -5.83%
Feb-08-23 08:00AM	Astria Therapeutics Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE (Business Wire) -6.83%
Feb-02-23 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.76%
Dec-19-22 04:01PM	Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) -6.01% +6.40%
Dec-15-22 06:10AM	Astria Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock (Business Wire)
06:00AM	Astria Therapeutics Announces Positive Preliminary Results from the Phase 1a Clinical Trial of STAR-0215 in Healthy Subjects (Business Wire)
Dec-02-22 04:00PM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.23%
Nov-10-22 04:10PM	Astria Therapeutics Reports Third Quarter 2022 Financial Results and Provides a Corporate Update (Business Wire) +9.81%
Nov-09-22 08:00AM	Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference (Business Wire) -5.37%
Nov-07-22 08:00AM	Astria Therapeutics to Present STAR-0215 Modeling and Simulation Data at the 2022 American College of Allergy, Asthma and Immunology Annual Meeting (Business Wire) -9.94%
Nov-02-22 08:00AM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-16-22 08:00AM	Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development (Business Wire)
Sep-06-22 08:00AM	Astria Therapeutics to Present at Upcoming Investment Conferences (Business Wire)
Sep-02-22 08:00AM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.11%
Aug-09-22 04:32PM	Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update (Business Wire)
Aug-04-22 08:00AM	Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema (Business Wire)
Aug-03-22 08:00AM	Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022 (Business Wire) +6.91%
Aug-02-22 08:00AM	Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-29-22 09:34AM	Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation (Simply Wall St.)
Jul-28-22 08:00AM	Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema (Business Wire) +8.56%
Jul-15-22 08:00AM	Astria Therapeutics Names Chris Morabito Chief Medical Officer (Business Wire) +6.84%

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Morabito Christopher	Chief Medical Officer	Apr 01 '24	Option Exercise	3.87	10,000	38,700	10,000	Apr 03 04:05 PM
Morabito Christopher	Chief Medical Officer	Apr 01 '24	Sale	13.59	10,000	135,939	0	Apr 03 04:05 PM
PERCEPTIVE ADVISORS LLC	Director	Feb 01 '24	Buy	12.09	2,481,350	29,999,522	4,873,721	Feb 05 05:02 PM
Morabito Christopher	Chief Medical Officer	Jan 29 '24	Option Exercise	3.87	9,200	35,604	9,200	Jan 30 05:03 PM
Morabito Christopher	Chief Medical Officer	Jan 26 '24	Option Exercise	3.87	800	3,096	800	Jan 30 05:03 PM
Morabito Christopher	Chief Medical Officer	Jan 29 '24	Sale	11.15	9,200	102,552	0	Jan 30 05:03 PM
Morabito Christopher	Chief Medical Officer	Jan 26 '24	Sale	11.02	800	8,812	0	Jan 30 05:03 PM
PERCEPTIVE ADVISORS LLC	Director	Dec 21 '23	Buy	6.20	740,000	4,588,000	2,392,371	Dec 22 02:51 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATXS

Astria Therapeutics Inc

Upgrade your FINVIZ experience